GlaxoSmithKline plc (GSK), a second largest pharma in the world with pharma revenues of £23,7 billion plus (US$37.7 billion) as at the end of the year 2009, has generated all-round performance during the fourth quarter and full year ended December 2009 on account of higher sales of vaccines, respiratory, anti-virals, and cardiovascular and urogenital. Its net profit has taken a jump of 36.8 per cent to £1,668 million from £1,017 million in the corresponding period of last year.

Its turnover, including pharmaceutical, OTC, oral healthcare and nutritional healthcare segments, increased by 17.1 per cent to £8,094 million from £6,910 million. Its pharmaceutical sales increased by 19.2 per cent to £6,916 million from £5,803 million. The sales of vaccines went up sharply by 91.3 per cent to £1,523 million from £796 million basically due to higher sales of Flu Pandemic which increased to £836 million from £17 million. GSK's sales of respiratory products increased by 10.6 per cent to £1,914 million and that of anti-virals increased by 11.8 per cent to £1,033 million. However, sales of CNS products and metabolic declined by 24.2 per cent and 13 per cent respectively during the quarter ended December 2009.

Andrew Witty, CEO, said, "Our strategy is delivering and I believe that GSK is now moving to a position where we can deliver our goal of long-term sustainable financial performance. 2009 saw GSK return to sales growth and I am confident of our prospects in 2010." The company increased 2009 dividend to 61 pens.

For the full year ended December 2009, GSK has recorded net profit growth of 20.3 per cent to £5,669 million from £4,712 million in the previous year. Its turnover increased by 16.5 per cent to £28,368 million from £24,352 million. The company's vaccines sales increased sharply by 46 per cent to £3,706 million from £2,539 million in the previous year. The respiratory sales moved up by 19.9 per cent to £6,977 million and that of anti-virals moved up by 29.4 per cent to £4,150 million. GSK's CNS sales declined by 35.5 per cent to £1,870 million from £2,897 million. Similarly, the sales of metabolic also moved down by 0.8 per cent to £1,181 million.

GSK's sales in US touched to £9,180 million as against £8894 million in the previous year, a growth of 3.2 per cent and that in Europe increased by 18.5 per cent to £7,681 million from £6,483 million. The sales in emerging market moved up to £6,605 million from £5,004 million in the year 2008. GSK received approvals for 12 products and it filed 11 new products. The R&D expenditure improved by 11.6 per cent to £4,106 million from £3,681 million. Its new R&D model fully operational and taking actions to improve R&D returns. Its 30 assets are in late-stage development.